Skip to main content

Table 1 Patient characteristics and CETC examination results

From: Influence of endocrine therapy on the ratio of androgen receptor (AR) to estrogen receptor (ER) positive circulating epithelial tumor cells (CETCs) in breast cancer

Clinico-pathological characteristics Number of patients (%) with CETCs Median of CETC counts P-value Median (%) of AR positive CETCs P-value Median (%) of ER positive CETCs P-value
Age (years)
  ≤ 50 26 (39) 85 0.001 90 0.98 50 0.91
  > 50 40 (61) 30 89 50
Tumor size
 T1 29 (44) 35 0.34 83 0.42 50 0.86
 T2 34 (51) 35 80 50
 T3 2 (3) 120 73 62
 n.a 1 (2)    
Lymph node metastasis
 Positive 25 (38) 40 0.63 86 0.04 50 0.63
 Negative 40 (61) 35 93 50
 n.a 1 (1)    
Distant metastasis
 Positive 7 (11) 85 0.11 88 0.99 49 0.97
 Negative 58 (88) 35 89 50
 n.a 1 (1)    
Stage
 I/II 49 (74) 30 0.009 90 0.93 51 0.16
 III/IV 17 (26) 95 89 62
HER2 status
 Positive 21 (32) 35 0.58 89 0.93 56 0.37
 Negative 45 (68) 35 90 52
ER/PR status
 Positive 51 (77) 35 0.97 87 0.74 52 0.82
 Negative 15 (23) 35 88 46
Radiation
 Yes 24 (36) 40 0.93 92 0.19 48 0.27
 No 34 (52) 40 88 52
 n.a 8 (12)    
Hormone receptor status
 TNBC 10 (16) 55 0.31 91 0.02 56 0.55
 ER/PR pos. 51 (84) 35 83 46
Hormone therapy
 Yes 33 (50) 35 0.77 89 0.57 47 0.07
 No 32 (49) 35 91 60
 n.a 1 (1)    
Chemotherapy
Yes 30 (45) 50 0.51 90 0.47 52 0.96
No 36 (55) 35 88 48
Tamoxifen therapy
 Yes 22 (33) 35 0.64 90 0.75 45 0.042
 No 43 (66) 35 91 58
 n.a 1 (1)    
Aromatase inhibitor
 Yes 19 (29) 50 0.29 85 0.22 50 0.35
 No 46 (70) 35 91 39
 n.a 1 (1)    
  1. Statistically significant values are in italics